biotech
Amgen Buys Ilypsa for $420 Million
Filed in archive Corporate and Industrial News by ruth on June 6, 2007
Amgen Buys Ilypsa for $420 Million
Biotech giant Amgen, Inc has agreed to buy Ilypsa, a privately-held, Sand Francisco based firm focusing on the development of drugs against kidney disease, for $420 million. Ilypsa's lead drug candidate, ILY101, is a phosphate binder for the treatment of abnormally high levels of phosphate in the blood in Chronic kidney disease (CKD) patients on hemodialysis.
ILY101 is an orally administered, non-absorbed polymeric agent that works by preventing the absorption of ingested phosphate. Studies suggest that ILY101 may have enhanced phosphate binding selectivity and capacity compared to currently available polymeric phosphate binding agents. ILY101 has completed Phase 2 trials in patients with CKD who are on hemodialysis.

More details regarding the acquisition from Amgen's press release.

Permalink: Amgen Buys Ilypsa for $420 Million
Tags: amgen  biotech  investment  merger  renal+disease  kidney+disease  500+Internal+Server+Error+read+timeou 
Trackback: http://publish.creative-weblogging.com/publish/mt-tb.pl/74005
img Addthis img Ask img Blinklist img del.icio.us img Digg img Fark img Facebook img Google img Lycos img Ma.gnolia Add this page to Mister Wong Mr Wong img Netscape img Netvousz img Newsvine img Reddit img StumbleUpon img Slashdot img Tailrank img Technorati img Wink img Yahoo

Vote for Amgen Buys Ilypsa for $420 Million:

  • Currently 8.50/10
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
Rating: 8.50 out of 4 vote(s) cast.
Subscribe
Share It
Popular posts from our other blogs:
RSSrss
See all blog subscribe options
Google google
What is RSS?
Yahoo! yahoo
Addthis Subscribe using any feed reader!
Bloglines Bloglines
Newsletter

TwitterFollow us on Twitter!